Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib in ErbB2 Positive Solid Tumors
NCT00447226Phase 2Terminated
- Sponsor
- GSK
- Start
- May 2007
- Primary completion
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lapatinib in ovarian cancer, gastric adenocarcinoma, esophageal adenocarcinoma (EAC), Uterine serous carcinoma (USC), bladder cancer, sponsored by GSK. Started May 2007; status: terminated.
02
Drugs
lapatinib
03
Conditions
ovarian cancergastric adenocarcinomaesophageal adenocarcinoma (EAC)Uterine serous carcinoma (USC)bladder cancer
Beyond the preview
Go deeper on NCT00447226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00447226.